img

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Research Report 2024

BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
According to Mr Accuracy reports’s new survey, global VPM1002 (Tuberculosis BCG Based Vaccine) market is projected to reach US$ 474.6 million in 2034, increasing from US$ 373.7 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole VPM1002 (Tuberculosis BCG Based Vaccine) market research.
Japan is the largest BCG Vaccine market with about 30% market share. North America is follower, accounting for about 29% market share.The key manufacturers are Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, GSBPL etc. Top 3 companies occupied about 77% market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global VPM1002 (Tuberculosis BCG Based Vaccine) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Vakzine Projekt Management (VPM)
Serum Institute of India
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination

Segment by Application


0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The VPM1002 (Tuberculosis BCG Based Vaccine) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 VPM1002 (Tuberculosis BCG Based Vaccine) Market Overview
1.1 Product Overview and Scope of VPM1002 (Tuberculosis BCG Based Vaccine)
1.2 VPM1002 (Tuberculosis BCG Based Vaccine) Segment by Dosage
1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Dosage (2024-2034)
1.2.2 0.5ml Package
1.2.3 1ml Package
1.2.4 2ml Package
1.2.5 Other
1.3 VPM1002 (Tuberculosis BCG Based Vaccine) Segment by Application
1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value by Application: (2024-2034)
1.3.2 0-5 Years Old
1.3.3 5-18 Years Old
1.3.4 18-45 Years Old
1.3.5 45-65 Years Old
1.3.6 ≥65 Years Old
1.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Estimates and Forecasts
1.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue 2018-2034
1.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales 2018-2034
1.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 VPM1002 (Tuberculosis BCG Based Vaccine) Market Competition by Manufacturers
2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Manufacturers (2018-2024)
2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Manufacturers (2018-2024)
2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Average Price by Manufacturers (2018-2024)
2.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Product Type & Application
2.7 VPM1002 (Tuberculosis BCG Based Vaccine) Market Competitive Situation and Trends
2.7.1 VPM1002 (Tuberculosis BCG Based Vaccine) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) Players Market Share by Revenue
2.7.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 VPM1002 (Tuberculosis BCG Based Vaccine) Retrospective Market Scenario by Region
3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region: 2018 Versus 2022 Versus 2034
3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region: 2018-2034
3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region: 2018-2024
3.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region: 2024-2034
3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2018-2034
3.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2018-2024
3.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2024-2034
3.4 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.4.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2018 VS 2022 VS 2034
3.4.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2034)
3.4.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.5.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2018 VS 2022 VS 2034
3.5.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2034)
3.5.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.6.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2018 VS 2022 VS 2034
3.6.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2034)
3.6.3 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.7.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2018 VS 2022 VS 2034
3.7.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2034)
3.7.3 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Facts & Figures by Country
3.8.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country: 2018 VS 2022 VS 2034
3.8.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2034)
3.8.3 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2018-2034)
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2018-2024)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2024-2034)
4.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2018-2034)
4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2018-2034)
4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2018-2024)
4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2024-2034)
4.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2018-2034)
4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Type (2018-2034)
5 Segment by Application
5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2018-2034)
5.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2018-2024)
5.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2024-2034)
5.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2018-2034)
5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2018-2034)
5.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2018-2024)
5.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2024-2034)
5.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2018-2034)
5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Vakzine Projekt Management (VPM)
6.1.1 Vakzine Projekt Management (VPM) Corporation Information
6.1.2 Vakzine Projekt Management (VPM) Description and Business Overview
6.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product Portfolio
6.1.5 Vakzine Projekt Management (VPM) Recent Developments/Updates
6.2 Serum Institute of India
6.2.1 Serum Institute of India Corporation Information
6.2.2 Serum Institute of India Description and Business Overview
6.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Product Portfolio
6.2.5 Serum Institute of India Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VPM1002 (Tuberculosis BCG Based Vaccine) Industry Chain Analysis
7.2 VPM1002 (Tuberculosis BCG Based Vaccine) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VPM1002 (Tuberculosis BCG Based Vaccine) Production Mode & Process
7.4 VPM1002 (Tuberculosis BCG Based Vaccine) Sales and Marketing
7.4.1 VPM1002 (Tuberculosis BCG Based Vaccine) Sales Channels
7.4.2 VPM1002 (Tuberculosis BCG Based Vaccine) Distributors
7.5 VPM1002 (Tuberculosis BCG Based Vaccine) Customers
8 VPM1002 (Tuberculosis BCG Based Vaccine) Market Dynamics
8.1 VPM1002 (Tuberculosis BCG Based Vaccine) Industry Trends
8.2 VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
8.3 VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
8.4 VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Competitive Situation by Manufacturers in 2022
Table 4. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) of Key Manufacturers (2018-2024)
Table 5. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Manufacturers (2018-2024)
Table 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market VPM1002 (Tuberculosis BCG Based Vaccine) Average Price (USD/Dose) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of VPM1002 (Tuberculosis BCG Based Vaccine), Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Product Type & Application
Table 12. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2018-2024) & (K Doses)
Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2018-2024)
Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2024-2034) & (K Doses)
Table 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2024-2034)
Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2018-2024)
Table 23. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2024-2034)
Table 25. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 26. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2024) & (K Doses)
Table 27. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2024-2034) & (K Doses)
Table 28. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 31. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2024) & (K Doses)
Table 32. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2024-2034) & (K Doses)
Table 33. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2018-2024) & (K Doses)
Table 37. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2024-2034) & (K Doses)
Table 38. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2024) & (K Doses)
Table 42. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2024-2034) & (K Doses)
Table 43. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2018-2024) & (K Doses)
Table 47. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2024-2034) & (K Doses)
Table 48. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Type (2018-2024)
Table 51. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Type (2024-2034)
Table 52. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2018-2024)
Table 53. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2024-2034)
Table 54. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Type (2018-2024)
Table 55. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Type (2024-2034)
Table 56. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2018-2024)
Table 57. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2024-2034)
Table 58. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Type (2018-2024)
Table 59. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Type (2024-2034)
Table 60. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Application (2018-2024)
Table 61. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses) by Application (2024-2034)
Table 62. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2018-2024)
Table 63. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2024-2034)
Table 64. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Application (2018-2024)
Table 65. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (US$ Million) by Application (2024-2034)
Table 66. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2018-2024)
Table 67. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2024-2034)
Table 68. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Application (2018-2024)
Table 69. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Application (2024-2034)
Table 70. Vakzine Projekt Management (VPM) Corporation Information
Table 71. Vakzine Projekt Management (VPM) Description and Business Overview
Table 72. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 73. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product
Table 74. Vakzine Projekt Management (VPM) Recent Developments/Updates
Table 75. Serum Institute of India Corporation Information
Table 76. Serum Institute of India Description and Business Overview
Table 77. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 78. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Product
Table 79. Serum Institute of India Recent Developments/Updates
Table 80. Key Raw Materials Lists
Table 81. Raw Materials Key Suppliers Lists
Table 82. VPM1002 (Tuberculosis BCG Based Vaccine) Distributors List
Table 83. VPM1002 (Tuberculosis BCG Based Vaccine) Customers List
Table 84. VPM1002 (Tuberculosis BCG Based Vaccine) Market Trends
Table 85. VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
Table 86. VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
Table 87. VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of VPM1002 (Tuberculosis BCG Based Vaccine)
Figure 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Type in 2022 & 2034
Figure 4. 0.5ml Package Product Picture
Figure 5. 1ml Package Product Picture
Figure 6. 2ml Package Product Picture
Figure 7. Other Product Picture
Figure 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Application in 2022 & 2034
Figure 10. 0-5 Years Old
Figure 11. 5-18 Years Old
Figure 12. 18-45 Years Old
Figure 13. 45-65 Years Old
Figure 14. ≥65 Years Old
Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size (2018-2034) & (US$ Million)
Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (2018-2034) & (K Doses)
Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) Average Price (USD/Dose) & (2018-2034)
Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) Report Years Considered
Figure 20. VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Manufacturers in 2022
Figure 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) Players: Market Share by Revenue in 2022
Figure 23. VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Figure 25. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2018-2034)
Figure 26. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2018-2034)
Figure 27. U.S. VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. Canada VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2018-2034)
Figure 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2018-2034)
Figure 31. Germany VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. France VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. U.K. VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Italy VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. Russia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2018-2034)
Figure 37. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2018-2034)
Figure 38. China VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. India VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Australia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Indonesia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Thailand VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Malaysia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Philippines VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2018-2034)
Figure 49. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2018-2034)
Figure 50. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Country (2018-2034)
Figure 54. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Country (2018-2034)
Figure 55. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 57. UAE VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 58. Global Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Type (2018-2034)
Figure 59. Global Revenue Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Type (2018-2034)
Figure 60. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Type (2018-2034)
Figure 61. Global Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Application (2018-2034)
Figure 62. Global Revenue Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) by Application (2018-2034)
Figure 63. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price (USD/Dose) by Application (2018-2034)
Figure 64. VPM1002 (Tuberculosis BCG Based Vaccine) Value Chain
Figure 65. VPM1002 (Tuberculosis BCG Based Vaccine) Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed